keyword
MENU ▼
Read by QxMD icon Read
search

ocriplasmin

keyword
https://www.readbyqxmd.com/read/29768451/intravitreal-ocriplasmin-for-the-treatment-of-vitreomacular-traction-and-macular-hole-a-study-of-efficacy-and-safety-based-on-nice-guidance
#1
Mahiul M K Muqit, Robin Hamilton, Jason Ho, Sally Tucker, Helen Buck
PURPOSE: To evaluate the real world clinical outcomes of intravitreal ocriplasmin in patients with vitreomacular traction (VMT) with and without full thickness macular holes (FTMH) treated according to NICE guidance. METHODS: Retrospective observational case series of 25 patients treated with a single intravitreal ocriplasmin injection between December 2013 and December 2015. Best corrected visual acuity and optical coherence tomography exams were performed to determine visual outcomes and anatomical VMT release and FTMH closure over time...
2018: PloS One
https://www.readbyqxmd.com/read/29621042/experience-with-ocriplasmin-in-patients-with-vitreomacular-traction-syndrome-a-retrospective-study-of-10-patients
#2
Caroline Bormann, Bianca C Apitzsch, Anke Habermann, Ute Hammer, Thomas Hammer
PURPOSE: To assess the efficacy of ocriplasmin in patients with vitreomacular traction (VMT) syndrome <1,500 μm with or without a full-thickness macular holes of <400 μm. METHODS: In this study, a retrospective analysis of 10 eyes of 10 patients with VMT who were treated with ocriplasmin between December 2014 and January 2016 was performed. Ocriplasmin 0.125 mg was injected only once in all cases. Outcome measures included the detachment of VMT, best-corrected visual acuity, the evaluation of optical coherence tomography, including the closure of full-thickness macular holes, and the reduction of macular edema (if present) and the decrease of metamorphopsia if present...
April 4, 2018: Retinal Cases & Brief Reports
https://www.readbyqxmd.com/read/29595569/spectral-domain-optical-coherence-tomography-findings-and-visual-outcome-after-treatment-for-vitreomacular-traction
#3
Peng Sun, Rachel M Tandias, Gina Yu, Jorge G Arroyo
PURPOSE: To evaluate the capacity of spectral domain optical coherence tomography macular findings to predict best-corrected visual acuity (BCVA) outcomes after treatment for symptomatic vitreomacular traction. METHODS: This consecutive, retrospective study included 24 patients (29 eyes) who experienced vitreomacular traction release with pneumatic vitreolysis (n = 9), intravitreal ocriplasmin (n = 6), or pars plana vitrectomy (n = 14). Preoperative and postoperative spectral domain optical coherence tomography images were used to determine the cone outer segment tips (COST) line, inner segment/outer segment line, and other frequently used features...
March 27, 2018: Retina
https://www.readbyqxmd.com/read/29566375/long-term-results-of-vitrectomy-for-macular-holes-after-failure-of-vitreolysis
#4
Allan Benarous, Yannick Le Mer
PURPOSE: Ocriplasmin injection may close some small-to-medium macular holes associated with vitreoretinal traction. If the treatment fails, does vitrectomy and gas injection yield the same results as primary surgery? MATERIAL AND METHODS: We report a retrospective case series study of 3 eyes of 3 consecutive patients operated on a few months after initial intravitreal injection of ocriplasmin and enlargement of the macular hole. The minimal follow-up period after surgery was 18 months...
March 22, 2018: Ophthalmologica. Journal International D'ophtalmologie
https://www.readbyqxmd.com/read/29468225/multimodal-imaging-of-macular-subretinal-deposits-following-intravitreal-ocriplasmin-injection
#5
Nicholas Chow, Thomas Hong, Andrew Chang
Purpose: Ocriplasmin is effective in closing macular holes due to vitreomacular traction. We present a case of macular subretinal material deposition observed with spectral-domain optical coherence tomography (SD-OCT) and multimodal imaging, following successful closure of a macular hole following intravitreal ocriplasmin injection. Observations: An 81-year-old male presented with decreased vision in the left eye due to a full-thickness macular hole secondary to vitreomacular traction...
March 2018: American Journal of Ophthalmology Case Reports
https://www.readbyqxmd.com/read/29411099/vitrectomy-for-optic-disc-pit-maculopathy-a-long-term-follow-up-study
#6
Ferdinando Bottoni, Matteo Cereda, Roberta Secondi, Sara Bochicchio, Giovanni Staurenghi
PURPOSE: To evaluate the clinical outcomes of vitrectomy with induction of posterior vitreous detachment for the treatment of optic disc pit maculopathy. METHODS: We retrospectively evaluated medical records and imaging studies of 11 consecutive patients with optic disc pit maculopathy who underwent vitrectomy at Sacco University Hospital, Milan, Italy, between October 2008 and December 2015. Induction of a posterior vitreous detachment (PVD) was the aim of our surgery...
April 2018: Graefe's Archive for Clinical and Experimental Ophthalmology
https://www.readbyqxmd.com/read/29402498/ocriplasmin-retinopathy-possible-cause-of-macular-hole-closure-failure
#7
P Udaondo, A Barreiro-González, S García-Delpech, R Martínez-Costa, Á Cisneros-Lanuza
CASE REPORT: A 53 year-old woman with a stage 2 macular hole received ocriplasmin injection as a first approach. She subsequently underwent pars plana vitrectomy due to enlargement of the hole post-injection. The visual gain following the surgery was minimal despite closure of the hole. This could be explained by outer retina atrophy as a consequence of potential toxic mechanisms related to ocriplasmin. DISCUSSION: Further studies may be warranted to fully understand the impact of ocriplasmin on long-term visual function...
May 2018: Archivos de la Sociedad Española de Oftalmología
https://www.readbyqxmd.com/read/29214073/assessment-of-ocriplasmin-effects-on-the-vitreoretinal-compartment-in-porcine-and-human-model-systems
#8
Bart Jonckx, Michael Porcu, Aurelie Candi, Isabelle Etienne, Philippe Barbeaux, Jean H M Feyen
Ocriplasmin (Jetrea®) is a recombinant protease used to treat vitreomacular traction. To gain insight into vitreoretinal observations reported after ocriplasmin treatment, we have developed an in vivo porcine ocriplasmin-induced posterior vitreous detachment (PVD) model in which we investigated vitreoretinal tissues by optical coherence tomography, histology, and cytokine profiling. Eight weeks postinjection, ocriplasmin yielded PVD in 82% of eyes. Subretinal fluid (85%) and vitreous hyperreflective spots (45%) were resolved by week 3...
2017: Journal of Ophthalmology
https://www.readbyqxmd.com/read/29206755/the-oasis-mp-1-substudy-characterization-of-the-effect-of-ocriplasmin-on-microperimetry-parameters
#9
SriniVas R Sadda, Pravin U Dugel, Victor H Gonzalez, Esmeralda Meunier, Petra Kozma
PURPOSE: To evaluate the effects of ocriplasmin and symptomatic vitreomacular adhesion resolution on visual fixation and macular sensitivity using microperimetry. METHODS: MP-1 parameters were analyzed from 3 OASIS sites after the use of standardized instruments and testing procedures over 24 months. RESULTS: A total of 27 patients (19 ocriplasmin, 8 sham) were evaluated. Mean distance of the preferred fixation locus to the anatomical center was farther in the sham group at baseline and farther in the sham versus ocriplasmin group throughout the study...
December 4, 2017: Retina
https://www.readbyqxmd.com/read/29141079/visual-function-response-to-ocriplasmin-for-the-treatment-of-vitreomacular-traction-and-macular-hole-the-oasis-study
#10
RANDOMIZED CONTROLLED TRIAL
Benedicte Lescrauwaet, Luc Duchateau, Thomas Verstraeten, Timothy L Jackson
Purpose: To assess the effect of ocriplasmin on visual function response (VFR) measured using visual acuity (VA) and vision-related quality of life, and to quantify the association between release of vitreomacular adhesion (VMA) at day 28 and VFR. Methods: Prespecified analysis of secondary endpoints from a randomized controlled trial. Of 220 participants with symptomatic VMA/vitreomacular traction (VMT), including VMT associated with a macular hole up to 400 μm, 146 received a single intravitreal injection of 125 μg ocriplasmin and 74 a sham injection...
November 1, 2017: Investigative Ophthalmology & Visual Science
https://www.readbyqxmd.com/read/29135889/comparison-of-resolution-of-vitreomacular-traction-after-ocriplasmin-treatment-or-vitrectomy
#11
Paula Scholz, Vasilena Sitnilska, Jelka Hess, Matthias Becker, Stephan Michels, Sascha Fauser
PURPOSE: To compare the functional and morphologic outcome of patients with vitreomacular traction (VMT) treated with either ocriplasmin treatment or vitrectomy. METHODS: Retrospective case series of patients treated with ocriplasmin or vitrectomy for VMT. OUTCOME MEASURES: resolution of VMT, change in outer retinal thickness, integrity of ellipsoid zone, subretinal fluid formation, and best-corrected visual acuity 2 weeks and 4 months after treatment...
November 9, 2017: Retina
https://www.readbyqxmd.com/read/29111823/surgical-results-in-ocriplasmin-candidates-with-symptomatic-vitreomacular-traction-syndrome
#12
Dario H Vasquez, Juan C Altamirano, Angel Casaus, Rodrigo A Del Valle, Roberto Gonzalez, Alejandro Gonzalez-De La Rosa, Jose Navarro-Partida, Martin A Vasquez, Arturo Santos
PURPOSE: To report surgical outcomes in a series of cases with symptomatic vitreomacular traction that met MIVI-TRUST (Microplasmin for intravitreous injection-traction release without surgical treatment) criteria for ocriplasmin use who underwent primary 25-gauge vitrectomy. MATERIALS AND METHODS: A single-center retrospective chart review study was performed in patients who underwent primary 25-gauge vitrectomy for symptomatic vitreomacular traction (VTM) from January 2013 through January 2016...
February 2018: Current Eye Research
https://www.readbyqxmd.com/read/29089354/calculating-the-individual-probability-of-successful-ocriplasmin-treatment-in-eyes-with-vmt-syndrome-a-multivariable-prediction-model-from-the-export-study
#13
Christoph Paul, Christine Heun, Hans-Helge Müller, Hans Hoerauf, Nicolas Feltgen, Joachim Wachtlin, Hakan Kaymak, Stefan Mennel, Michael Janusz Koss, Sascha Fauser, Mathias M Maier, Ricarda G Schumann, Simone Mueller, Petrus Chang, Steffen Schmitz-Valckenberg, Sara Kazerounian, Peter Szurman, Albrecht Lommatzsch, Thomas Bertelmann
BACKGROUND/AIMS: To evaluate predictive factors for the treatment success of ocriplasmin and to use these factors to generate a multivariate model to calculate the individual probability of successful treatment. METHODS: Data were collected in a retrospective, multicentre cohort study. Patients with vitreomacular traction (VMT) syndrome without a full-thickness macular hole were included if they received an intravitreal injection (IVI) of ocriplasmin. Five factors (age, gender, lens status, presence of epiretinal membrane (ERM) formation and horizontal diameter of VMT) were assessed on their association with VMT resolution...
October 31, 2017: British Journal of Ophthalmology
https://www.readbyqxmd.com/read/29040800/ocriplasmin-for-symptomatic-vitreomacular-adhesion
#14
REVIEW
James E Neffendorf, Varo Kirthi, Edward Pringle, Timothy L Jackson
BACKGROUND: Symptomatic vitreomacular adhesion (sVMA) is a recognised cause of visual loss and by tradition has been managed by pars plana vitrectomy (PPV). A less invasive alternative to surgery in some people is enzymatic vitreolysis, using an intravitreal injection of ocriplasmin. OBJECTIVES: To assess the efficacy and safety of ocriplasmin compared to no treatment, sham or placebo for the treatment of sVMA. SEARCH METHODS: We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (which contains the Cochrane Eyes and Vision Trials Register) (2017, Issue 1), MEDLINE Ovid (1946 to 24 February 2017), Embase Ovid (1947 to 24 February 2017), PubMed (1946 to 24 February 2017), the ISRCTN registry (www...
October 17, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28954271/impact-of-preinjection-spectral-domain-optical-coherence-tomography-findings-in-the-use-of-intravitreal-ocriplasmin-in-a-clinical-setting
#15
Christian Wertheimer, Christos Haritoglou, Peter Laubichler, Armin Wolf, Kathrin Kaessmann, Ricarda G Schumann, Siegfried Priglinger, Wolfgang J Mayer
PURPOSE: To investigate the impact of spectral domain optical coherence tomography (SD-OCT) morphological predictive markers on visual acuity and outcome using ocriplasmin for macular hole and vitreomacular traction syndrome. METHODS: A series of 40 patients in a retrospective study received intravitreal ocriplasmin. The primary endpoint was defined as morphological resolution of vitreomacular traction or closure of a macular hole. We analyzed the impact of pre- and postinjection SD-OCT findings on the outcome and visual acuity...
September 28, 2017: Ophthalmologica. Journal International D'ophtalmologie
https://www.readbyqxmd.com/read/28857483/intravitreal-gas-for-symptomatic-vitreomacular-adhesion-a-synthesis-of-the-literature
#16
REVIEW
James E Neffendorf, Andrew R H Simpson, David H W Steel, Riti Desai, Dominic A McHugh, Edward Pringle, Timothy L Jackson
Symptomatic vitreomacular adhesion (sVMA) is defined as visual loss secondary to foveal damage from vitreomacular traction (VMT) and includes isolated VMT, impending macular hole (MH), and full-thickness MH with persisting vitreous attachment. Management options include pars plana vitrectomy (PPV), intravitreal ocriplasmin, intravitreal gas injection or observation. This synthesis of the literature aimed to assess the safety and efficacy of intravitreal gas for sVMA. Articles describing patients with VMT or MH treated with intravitreal expansile gas were selected by systematic literature review using MEDLINE, EMBASE, and the Cochrane Database of Controlled Trials (CENTRAL) up to September 2016...
August 31, 2017: Acta Ophthalmologica
https://www.readbyqxmd.com/read/28791829/intravitreal-ocriplasmin-a-breakthrough-in-the-treatment-of-vitreomacular-traction
#17
REVIEW
Anna E Mec-Słomska, Joanna Adamiec-Mroczek, Ewa Kuźmicz, Marta Misiuk-Hojło
Vitreoretinal interface pathologies, such as vitreomacular traction syndrome, epiretinal membranes and macular holes are sight-threatening conditions and one of the important causes of vision defects and vision loss. To this date, vigilance with observation of how the vitreomacular traction resolves, or vitreoretinal surgery in more severe cases, were the only treatment options. Recent rapid progress in ophthalmology, especially in diagnostic and visualization techniques, provided better insight into the mechanisms taking place on the vitreoretinal surface, which enabled a more accurate selection of treatment options...
May 2017: Advances in Clinical and Experimental Medicine: Official Organ Wroclaw Medical University
https://www.readbyqxmd.com/read/28767551/ocriplasmin-for-vitreomacular-traction-looking-outside-the-macula-a-wide-field-optical-coherence-tomography-study
#18
Matteo G Cereda, Chiara Preziosa, Isabella DʼAgostino, Mariano Cozzi, Ferdinando Bottoni, Marco Pellegrini, Andrea Giani, Giovanni Staurenghi
PURPOSE: To evaluate baseline features and morphologic changes of vitreoretinal adhesion and outer retinal layers outside the macula after intravitreal ocriplasmin injection. To study the relation between vitreous detachment and attenuation of retinal outer segments signal. METHODS: Retrospective cases series of 15 eyes. Each eye was scanned with the 55° wide-field optical coherence tomography lens in 6 different locations, three horizontal B-scan (central, temporal, and nasal) and three vertical B-scan (central, superior, and inferior) at baseline, 1 week, 1 month, 3 months, and 6 months after injection...
August 1, 2017: Retina
https://www.readbyqxmd.com/read/28755165/assessment-of-intravitreal-ocriplasmin-treatment-for-vitreomacular-traction-in-clinical-practice
#19
Ricarda G Schumann, Julian Langer, Denise Compera, Katharina Luedtke, Markus M Schaumberger, Thomas Kreutzer, Wolfgang J Mayer, Armin Wolf, Siegfried G Priglinger
PURPOSE: To assess treatment effects following intravitreal injection of ocriplasmin for vitreomacular traction (VMT), with or without full-thickness macular hole (FTMH), in real-life setting. METHODS: This is a monocentric, retrospective, consecutive series of 82 eyes from 82 patients who underwent ocriplasmin treatment between July 2013 and December 2016. We included 57 eyes with pure VMT, 17 eyes with small FTMHs, and eight eyes with medium FTMHs. Primary outcome measures were VMT release and MH closure rates...
November 2017: Graefe's Archive for Clinical and Experimental Ophthalmology
https://www.readbyqxmd.com/read/28699051/-assessing-the-added-benefit-of-new-ophthalmic-drugs-which-additional-insights-can-be-extracted-from-the-early-benefit-assessment
#20
REVIEW
M Appelrath, G Glaeske
Until now six ophthalmic agents have undergone the German early benefit assessment according to § 35a Social Security Code (SGB) V in a total of eleven indications. Only one agent (ocriplasmin) was recognized by the Federal Joint Committee as having an added benefit based on submitted study data for a subpopulation (indication of a considerable added benefit, limited for 5 years) and another agent, idebenone, received an added benefit due to its orphan drug designation (proof of a not quantifiable added benefit, limited for 2 years)...
December 2017: Der Ophthalmologe: Zeitschrift der Deutschen Ophthalmologischen Gesellschaft
keyword
keyword
55513
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"